Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wayne C Levy

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
Journal of the American College of Cardiology|July 16, 2011
The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failureBonnie Ky, Benjamin French, Kosha Ruparel, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 10, 2013
Impact of renal dysfunction on the Seattle Heart Failure ModelKairav P Vakil, Todd Dardas, Sunil Dhar, et al.
American Heart Journal|June 2, 2024
Seattle proportional risk model in GISSI-HF: Estimated benefit of ICD in patients with EF less than 50Lee B Bockus, Ramin Shadman, Jeanne E Poole, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|March 1, 2020
Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon DeviceJanusz Lipiecki, David M Kaye, Klaus K Witte, et al.
American Heart Journal|December 19, 2015
Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablationKairav P Vakil, Henri Roukoz, Roderick Tung, et al.
JAMA Cardiology|July 21, 2017
Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure TrialSelcuk Adabag, Kristen K Patton, Alfred E Buxton, et al.
The American Journal of Cardiology|April 21, 2012
Performance of the Seattle Heart Failure Model in implantable defibrillator patients treated with cardiac resynchronization therapyTim Smith, Wayne C Levy, Beat A Schaer, et al.
Journal of Cardiac Failure|February 8, 2018
Adverse Effects of Delayed Transplant Listing Among Patients With Implantable Left Ventricular Assist DevicesTodd F Dardas, Richard K Cheng, Claudius Mahr, et al.
Journal of Cardiac Failure|June 3, 2014
Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTIONYanhong Li, Wayne C Levy, Matthew P Neilson, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|February 29, 2012
Comparison of observed survival after ventricular assist device placement versus predicted survival without assist device using the Seattle heart failure modelSalpy V Pamboukian, Jose A Tallaj, Robert N Brown, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
Journal of the American College of Cardiology|July 16, 2011
The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failureBonnie Ky, Benjamin French, Kosha Ruparel, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 10, 2013
Impact of renal dysfunction on the Seattle Heart Failure ModelKairav P Vakil, Todd Dardas, Sunil Dhar, et al.
American Heart Journal|June 2, 2024
Seattle proportional risk model in GISSI-HF: Estimated benefit of ICD in patients with EF less than 50Lee B Bockus, Ramin Shadman, Jeanne E Poole, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|March 1, 2020
Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon DeviceJanusz Lipiecki, David M Kaye, Klaus K Witte, et al.
American Heart Journal|December 19, 2015
Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablationKairav P Vakil, Henri Roukoz, Roderick Tung, et al.
JAMA Cardiology|July 21, 2017
Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure TrialSelcuk Adabag, Kristen K Patton, Alfred E Buxton, et al.
The American Journal of Cardiology|April 21, 2012
Performance of the Seattle Heart Failure Model in implantable defibrillator patients treated with cardiac resynchronization therapyTim Smith, Wayne C Levy, Beat A Schaer, et al.
Journal of Cardiac Failure|February 8, 2018
Adverse Effects of Delayed Transplant Listing Among Patients With Implantable Left Ventricular Assist DevicesTodd F Dardas, Richard K Cheng, Claudius Mahr, et al.
Journal of Cardiac Failure|June 3, 2014
Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTIONYanhong Li, Wayne C Levy, Matthew P Neilson, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|February 29, 2012
Comparison of observed survival after ventricular assist device placement versus predicted survival without assist device using the Seattle heart failure modelSalpy V Pamboukian, Jose A Tallaj, Robert N Brown, et al.
Pageof 17